- The FDA has granted Orphan Drug Designation to Relief Therapeutics Holding AG's RLFTF for RLF-100 (aviptadil), an inhaled formulation, for sarcoidosis.
- RLF-100 is a synthetic form of vasoactive intestinal peptide.
- Sarcoidosis is a rare disease in which the inflammatory process involves the alveoli (air sacs), small bronchi, and small blood vessels.
- RLF-100 is in late-stage clinical testing in the U.S. for respiratory deficiency due to COVID-19.
- Price Action: RLFTF shares closed at $0.24 on Monday.
- Related content: Benzinga's Full FDA Calendar.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
